SCI-GROUP AS
Org no 988 214 205 | Oslo, Norway | E-post: jj@sci-group.no
Next-generation cryopreservation
Sci-Group has developed an entirely new freezing technology that enables safe, rapid, and efficient cryopreservation of cells — without, or strongly reduced, the use of cytotoxic chemical cryoprotectants such as DMSO. Our solution minimizes exposure to cytotoxic substances, simplifies workflows, and supports safer applications in both research and clinical settings.
How does our CryoEmbla technology work?
Traditional cryopreservation has for decades relied on chemical cryoprotectants (CPAs) such as DMSO to prevent cell death during freezing. Although DMSO has been effective, it presents significant challenges: toxicity for patients, reduced cell viability, complicated handling, and strict regulatory requirements.
Sci-Group has challenged this standard with CryoEmbla—a patented technology that freezes cells in a controlled and precise manner, without, or strongly reduced, the need for cytotoxic chemical cryoprotectants such as DMSO.
By optimizing the freezing curve and controlling ice formation at the cellular level, our approach helps maintain cell viability and integrity, while making the process much faster and simpler than traditional methods.
Key advantages of CryoEmbla:
- Cytotoxic chemical cryoprotectants: Strongly reduced need for DMSO or other cytotoxic additives, or noen at all.
- Maintains cell viability: Demonstrated cell survival after thawing.
- Fast and efficient: Freezing takes less than 15 minutes, compared to several hours with traditional methods.
- Simplified workflow: Less need for washing and handling, fewer sources of error, and lower risk of cell loss.
- Supports safer clinical use: Reduces the risk of cytotoxic exposure for patients and can simplify regulatory processes.
Preserves cells and tissues without toxic additives – safer for both patients and research.
From several hours to minutes – efficient freezing with high cell survival.
Developed and tested in Norway, protected by international patents.
Technological principle
The core of CryoEmbla is an advanced, controlled freezing process that precisely regulates both temperature and ice formation. This prevents cell damage from ice crystals and preserves both viability and function—without the need for chemical additives.
The technology has been tested with excellent results on various cell types, including CHO-K1 cells, and is continuously being developed to meet the needs of research, industry, and clinical applications.
Areas of application
Sci-Group’s technology opens new opportunities within:
- Cell and gene therapy
- Biobanking and research
- Fertility treatment (IVF)
- Agriculture and food security
- Conservation and biodiversity preservation
Patented and protected
The CryoEmbla technology is patented in both Europe and the USA, giving Sci-Group a unique position in a market with rapidly growing demand for safe, effective, and cytotoxic chemical-free cryopreservation solutions.
Join us – become a partner
Partner with us and expand your possibilities in the future of safe and efficient cryopreservation.
Interested? Leave your info here & we’ll get back to you.